Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
Stocks · News reference
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stocks bucked the selloff.
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
Arrowhead Pharmaceuticals shares are trading lower. The company announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, RNAi therapeutic dimer for the treatment of mixed hyperlipidemia.
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.